Mayer M P
Departement de Biochimie Médicale, Centre Médical Universitaire, Genève 4, Switzerland.
Gene. 1995 Sep 22;163(1):41-6. doi: 10.1016/0378-1119(95)00389-n.
A new set of cloning vectors derived from pBlueScript (Stratagene, La Jolla, CA, USA) is presented. The ampicillin-resistance-encoding gene (ApR) of pBlueScript has been replaced by genes encoding resistance to either kanamycin (KmR) or tetracycline (TcR). The origin of DNA replication (ori), conferring to pBlueScript a very high-copy-number (500-700 copies/chromosome), has been replaced by the pBR322 ori (15-20 copies/chromosome) or the P15A ori (10-12 copies/chromosome) [Sambrook et al.: Molecular Cloning. A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989]. Therefore, eight new vectors with different drug selection markers and low, medium or high plasmid copy-number were created which are compatible with each other (ColE1 ori and P15A ori) and can be selected to replace one another. These vectors were further modified by the insertion of an expression cassette based on the promoter and AraC repressor/activator of the ara operon, which allows high-level expression, extremely tight regulation and very inexpensive induction. High-level expression of one or two genes within the same cell is demonstrated.
本文介绍了一组新的克隆载体,它们源自pBlueScript(美国加利福尼亚州拉霍亚的Stratagene公司)。pBlueScript的氨苄青霉素抗性编码基因(ApR)已被编码卡那霉素抗性(KmR)或四环素抗性(TcR)的基因所取代。赋予pBlueScript非常高拷贝数(500 - 700个拷贝/染色体)的DNA复制起点(ori)已被pBR322 ori(15 - 20个拷贝/染色体)或P15A ori(10 - 12个拷贝/染色体)所取代[Sambrook等人:《分子克隆实验指南》,第2版。冷泉港实验室出版社,纽约冷泉港,1989年]。因此,创建了八个具有不同药物选择标记以及低、中或高质粒拷贝数的新载体,它们彼此兼容(ColE1 ori和P15A ori),并且可以被选择相互替换。这些载体通过插入基于ara操纵子的启动子和AraC阻遏物/激活物的表达盒进一步修饰,该表达盒允许高水平表达、极其严格的调控以及非常廉价的诱导。证明了同一细胞内一个或两个基因的高水平表达。